| Literature DB >> 29636734 |
Nicole Roschanski1, Jennie Fischer2, Linda Falgenhauer3, Michael Pietsch4, Sebastian Guenther1, Lothar Kreienbrock5, Trinad Chakraborty3, Yvonne Pfeifer4, Beatriz Guerra2, Uwe H Roesler1.
Abstract
Carbapenems are last-resort antibiotics used in human medicine. The increased detection of carbapenem-resistant Enterobacteriaceae (CRE) is therefore worrying. In 2011 we reported the first livestock-associated VIM-1-producing Salmonella (S.) enterica serovar Infantis (R3) isolate from dust, sampled in a German chicken fattening farm. Due to this observation we retrospectively investigated more than 536 stored bacterial cultures, isolated from 45 chicken fattening farms during the years 2011 and 2012. After a non-selective overnight incubation, the bacteria were transferred to selective media. Escherichia (E.) coli and Salmonella growing on these media were further investigated, including antibiotic susceptibility testing, carbapenemase gene screening and whole genome sequencing (WGS). In total, four CRE were found in three out of 45 investigated farms: Besides R3, one additional Salmonella (G-336-1a) as well as two E. coli isolates (G-336-2, G-268-2). All but G-268-2 harbored the blaVIM-1 gene. Salmonella isolates R3 and G-336-1 were closely related although derived from two different farms. All three blaVIM-1-encoding isolates possessed identical plasmids and the blaVIM-1- containing transposon showed mobility at least in vitro. In isolate G-268-2, the AmpC beta-lactamase gene blaCMY-2 but no known carbapenemase gene was identified. However, a transfer of the phenotypic resistance was possible. Furthermore, G-268-2 contained the mcr-1 gene, combining phenotypical carbapenem- as well as colistin resistance in one isolate. Carbapenem-resistant Enterobacteriaceae have been found in three out of 45 investigated chicken flocks. This finding is alarming and emphasizes the importance of intervention strategies to contain the environmental spread of resistant bacteria in animals and humans.Entities:
Keywords: Germany; VIM-1 producing Enterobacteriaceae; antimicrobial resistance; broiler; carbapenems; livestock; plasmids
Year: 2018 PMID: 29636734 PMCID: PMC5880886 DOI: 10.3389/fmicb.2018.00538
Source DB: PubMed Journal: Front Microbiol ISSN: 1664-302X Impact factor: 5.640
Characteristics of carbapenem-resistant E. coli and S. Infantis isolates including their respective transformants derived from whole genome data analyses.
| R3 | 1 | IncHI2 [ST-1] | ||
| G-336-1a | 78 | IncHI2 [ST-1] | ||
| TG-336-1 | – | IncHI2 [ST-1] | ||
| G-336-2 | 78 | IncI1 [ST-12], IncHI2 [ST-1], IncF [F18:A6:B1] | ||
| TG-336-2_VIM | – | IncHI2 [ST-1] | ||
| TG-336-2_VIM+CMY | – | IncI1 [ST-12] | ||
| TG336-2_CMY | – | IncI1 [ST-12] | ||
| G-268-2 | 54 | ColRNAI, IncX1, p0111, IncX4, IncQ1, IncB/O/K/Z, IncF [F-:A1:B1] | ||
| NEB10-beta | None | None | ||
Previously identified by Fischer et al. (.
Figure 1Circular visualization and comparison of blaVIM-1-carrying IncHI2 plasmid sequences from S. Infantis as well as E. coli isolates derived from German chicken- as well as pig fattening farms and their transformants using BRIG. WT, wildtype; T, transformed E. coli NEB10®-beta.
Figure 2Plasmid content of donor strains and transformants (S1-PFGE). Information about respective replicon types and the resistance gene localization derived from the whole genome data analysis. WT, wildtype; T, transformed E. coli NEB10®-beta.
Antibiotic susceptibilities of wildtype strains and tranformants.
| 1/east | R3 (Fischer et al., | ≥128 | ≥128 | ≥64 | ≥64 | 8 | ≤1 | 8 | ≥16 | ≤2 | 2 | 8 | 0.5 | ≤0.5 | ≤16 | ≤0.5 | ≥320 | |
| 54/east | G-268-2 | ≥128 | ≥128 | ≥64 | ≥64 | 8 | ≥64 | ≥16 | 8 | 4 | ≤1 | 2 | ≥4 | ≤0.5 | ≤16 | 8 | ≥320 | |
| TG268-2_CMY | ≥128 | ≥128 | ≥64 | ≥64 | 16 | ≥64 | 8 | 4 | 4 | ≤1 | ≤1 | ≤0.25 | ≤0.5 | ≤16 | ≤0.5 | ≤20 | ||
| TG268-2_Mcr-1 | ≤4 | ≤4 | ≤1 | ≤1 | ≤1 | ≤1 | ≤0.25 | ≤0.25 | ≤2 | ≤1 | ≤1 | ≤0.25 | ≤0.5 | ≤16 | 8 | ≤20 | ||
| 78/south | G-336-1a | 64 | 64 | 32 | ≥64 | ≥64 | ≤1 | ≥16 | disc. | ≤2 | ≤1 | 2 | 0.5 | ≤0.5 | ≤16 | ≤0.5 | ≤20 | |
| TG336-1 | ≥128 | ≥128 | ≥64 | ≥64 | 16 | ≤1 | 8 | 8 | ≤2 | ≤1 | 4 | 0.5 | ≤0.5 | ≤16 | ≤0.5 | ≤20 | ||
| 78/ south | G-336-2 | ≥128 | ≥128 | ≥64 | ≥64 | 16 | 16 | ≥16 | ≥16 | ≤2 | ≤1 | 8 | 1 | ≤0.5 | ≤16 | ≤0.5 | ≤20 | |
| TG336-2_VIM | ≥128 | ≥128 | ≥64 | ≥64 | 16 | ≤1 | 4 | disc. | ≤2 | ≤1 | 8 | 0.5 | ≤0.5 | ≤16 | ≤0.5 | ≤20 | ||
| TG-336-2_VIM+CMY | ≥128 | ≥128 | ≥64 | ≥64 | ≥64 | ≥64 | 8 | ≥16 | ≤2 | 4 | ≥16 | 0.5 | ≤0.5 | ≤16 | ≤0.5 | ≤20 | ||
| TG336-2_CMY | ≥128 | ≥128 | ≥64 | ≥64 | 2 | ≥64 | 0.5 | ≤0.25 | ≤2 | ≤1 | ≤1 | ≤0.25 | ≤0.5 | ≤16 | ≤0.5 | ≤20 | ||
| NEB10-beta | ≤4 | ≤4 | ≤1 | ≤1 | ≤1 | ≤1 | ≤0.25 | ≤0.25 | ≤2 | ≤1 | ≤1 | ≤0.25 | ≤0.5 | ≤16 | ≤0.5 | ≤20 | ||
| NEB5-alpha | ≤4 | ≤4 | ≤1 | ≤1 | ≤1 | ≤1 | ≤0.25 | ≤0.25 | ≤2 | ≤1 | ≤1 | ≤0.25 | ≤0.5 | ≤16 | ≤0.5 | ≤20 | ||
PIP, piperacillin; PTZ, piperacillin-tazobactam; CTX, cefotaxime; CAZ, ceftazidime; FEP, cefepime; ATM, aztreonam; IPM, imipenem; MEM, meropenem; AMK, amikacin; GEN, gentamicin; TBM, tobramycin; CIP, ciprofloxacin; TGC, tigecycline; FOF, fosfomycin; CST, colistin; SXT, trimethoprim-sulfamethoxazole.
disc., run discontinued; n.d., not determined; ST, sequence type.